troglitazone has been researched along with Pulmonary Fibrosis in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pulmonary fibrosis is regulated by transforming growth factor-β (TGF-β) and peroxisome proliferator-activated receptor-gamma (PPARγ)." | 1.72 | Advancing the Adverse Outcome Pathway for PPARγ Inactivation Leading to Pulmonary Fibrosis Using Bradford-Hill Consideration and the Comparative Toxicogenomics Database. ( Choi, J; Jeong, J, 2022) |
| "Pulmonary fibrosis is characterized by alterations in fibroblast phenotypes resulting in excessive extracellular matrix accumulation and anatomic remodeling." | 1.35 | PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. ( Gangireddy, SR; Hogaboam, CM; Hu, B; Keshamouni, VG; Milam, JE; Phan, SH; Reddy, RC; Standiford, TJ; Thannickal, VJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, J | 1 |
| Choi, J | 1 |
| Milam, JE | 1 |
| Keshamouni, VG | 1 |
| Phan, SH | 1 |
| Hu, B | 1 |
| Gangireddy, SR | 1 |
| Hogaboam, CM | 1 |
| Standiford, TJ | 1 |
| Thannickal, VJ | 1 |
| Reddy, RC | 1 |
2 other studies available for troglitazone and Pulmonary Fibrosis
| Article | Year |
|---|---|
Advancing the Adverse Outcome Pathway for PPARγ Inactivation Leading to Pulmonary Fibrosis Using Bradford-Hill Consideration and the Comparative Toxicogenomics Database.
Topics: Adverse Outcome Pathways; Cell Survival; Cells, Cultured; Databases, Factual; Humans; PPAR gamma; Pu | 2022 |
PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Cell Differentiation; Cell Division; Cells, Culture | 2008 |